Search Results - "Dilley, Deanne"

A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis by Alexis, Andrew F., Gooderham, Melinda, Kwatra, Shawn G., Amin, Ahmad, Taylor, Susan, Espaillat, Ramon, Rettig, Trisha, Wu, Tianshuang, Shi, Linyu, Kaldas, Mark I., Dilley, Deanne M., Sinvhal, Ranjeeta, Nduaka, Chudy, Lockshin, Benjamin

“…Introduction Historically, patients with skin of color are underdiagnosed with psoriasis and underrepresented in clinical trials. In this study, we assess the…”
Get full text

Randomized double-blind comparison of cognitive and EEG effects of lacosamide and carbamazepine by Meador, Kimford J, Loring, David W, Boyd, Alan, Echauz, Javier, LaRoche, Suzette, Velez-Ruiz, Naymee, Korb, Pearce, Byrnes, William, Dilley, Deanne, Borghs, Simon, De Backer, Marc, Story, Tyler, Dedeken, Peter, Webster, Elizabeth

“…Abstract Differential effectiveness of antiepileptic drugs (AEDs) is more commonly determined by tolerability than efficacy. Cognitive effects of AEDs can…”
Get full text

Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial by Liu, Edwin, Dilley, Deanne, McDonough, Belinda, Stockis, Armel, Daniels, Tony

“…Objective This trial evaluated the short-term safety and tolerability, steady-state pharmacokinetics, and preliminary efficacy of brivaracetam oral solution in…”
Get full text

Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy by Klein, Pavel, Biton, Victor, Dilley, Deanne, Barnes, Matthew, Schiemann, Jimmy, Lu, Sarah

“…Summary Objectives An intravenous (IV) formulation of brivaracetam (BRV), a selective, high‐affinity ligand for synaptic vesicle protein 2A, has been…”
Get full text

44063 Short Term Efficacy and Racial and Ethnic Diversity in Risankizumab Phase 3 Clinical Trials for Treatment of Moderate-to-Severe Plaque Psoriasis by Alexis, Andrew, Gooderham, Melinda, Kwatra, Shawn G., Amin, Ahmad, Espaillat, Ramon, Kaldas, Mark, Liu, Ran, Dilley, Deanne M., Sinvhal, Ranjeeta, Nduaka, Chudi, Lockshin, Benjamin

Get full text

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies by Guttman-Yassky, Emma, Thyssen, Jacob P., Silverberg, Jonathan I., Papp, Kim A., Paller, Amy S., Weidinger, Stephan, Chih-ho Hong, H., Hendrickson, Barbara, Dilley, Deanne, Tenorio, Allan R., Ladizinski, Barry, Chu, Alvina D., Liu, John, Irvine, Alan D.

“…Upadacitinib is a selective reversible Janus kinase (JAK) inhibitor with established efficacy in moderate-to-severe atopic dermatitis (AD). We evaluated the…”
Get full text

533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure by Bunick, Christopher, Chovatiya, Raj, Guttman, Emma, Shahriari, Mona, Boguniewicz, Mark, Gao, Xinghua, Greiwe, Justin, Blauvelt, Andrew, Schuttelaar, Marie L A, Irvine, Alan D, Levy, Gweneth F, Platt, Andrew, Dilley, Deanne, Teixeira, Henrique, Altman, Katherine, Grada, Ayman, Silverberg, Jonathan

“…Abstract Introduction/Background Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease characterized by intense itch and eczematous skin…”
Get full text

427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies by Silverberg, Jonathan I, Bunick, Christopher G  , Lio, Peter, Guttman-Yassky, Emma, Boguniewicz, Mark , Blauvelt, Andrew, Bieber, Thomas , Thyssen, Jacob P, Suravaram, Smitha , Khan, Nasser S, Dilley, Deanne M  , Teixeira, Henrique D, Vigna, Namita V  , Gamelli, Amy, Grada, Ayman, Irvine, Alan D

“…Abstract Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by intense itch and eczematous skin lesions that can impact individuals…”
Get full text

Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – An open-label trial by Ferreira, Jose A., Le Pichon, Jean-Baptiste, Abdelmoity, Ahmed T., Dilley, Deanne, Dedeken, Peter, Daniels, Tony, Byrnes, William

“…•Open-label fixed-titration trial of lacosamide in children aged 6 month–≤17 years.•Adjunctive lacosamide ≤12 mg/kg/day was generally well tolerated in…”
Get full text

Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide‐naive patients with partial‐onset seizures by Fountain, Nathan B., Krauss, Gregory, Isojarvi, Jouko, Dilley, Deanne, Doty, Pamela, Rudd, G. David

“…Summary Purpose:  To examine the safety and tolerability of rapidly initiating adjunctive lacosamide via a single intravenous loading dose followed by…”
Get full text

Comparative Cognitive Effects of Lacosamide versus Carbamazepine (P3.191) by Loring, David, Meador, Kimford, Boyd, Alan, Byrnes, William, Dilley, Deanne, Borghs, Simon, De Backer, Marc, Story, Tyler, Dedeken, Peter, Webster, Elizabeth

“…Abstract only…”
Get full text

Prospective Open-Label, Single-Arm, Multicenter, Safety, Tolerability, and Pharmacokinetic Studies of Intravenous Levetiracetam in Children With Epilepsy by Weinstock, Arie, Ruiz, Matilde, Gerard, Danielle, Toublanc, Nathalie, Stockis, Armel, Farooq, Osman, Dilley, Deanne, Karmon, Yuval, Elgie, Mary Jo, Schiemann-Delgado, Jimmy

“…Levetiracetam given via intravenous administration has been shown to be an effective alternative in adults with epilepsy when oral administration is not…”
Get full text